Роль бендамустина в лечении В-клеточных неходжкинских лимфом

Обложка

Цитировать

Полный текст

Аннотация

Бендамустин - алкилирующий агент с уникальной структурой, у которого отсутствует перекрестная резистентность с другими представителями этой группы. На основании данных клинических рандомизированных исследований III фазы бендамустин в монорежиме и комбинации с ритуксимабом проявил себя в качестве перспективного звена для лечения больных индолентными неходжкинскими лимфомами и пожилых пациентов с лимфомой из клеток зоны мантии как в 1-й линии, так и в случае рецидивов и рефрактерного течения. Использование комбинаций с бендамустином продемонстрировало терапевтическое преимущество в сочетании с благоприятным профилем токсичности и лучшим качеством жизни больных по сравнению со стандартным лечением по схеме R-CHOP или R-CVP. В настоящее время изучаются комбинации бендамустина с новыми противоопухолевыми агентами, включая ибрутиниб или иделалисиб. Эта статья посвящена анализу имеющихся клинических данных, также представлены практические советы по использованию бендамустина в рутинной практике, в том числе рекомендации по дозировке, профилактике осложнений, инфузионных и кожных реакций, а также оппортунистических инфекций.

Об авторах

Лали Галимовна Бабичева

ФГБОУ ДПО РМАНПО

Email: lalibabicheva@mail.ru
канд. мед. наук, доц. каф. онкологии и паллиативной медицины 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

Ирина Владимировна Поддубная

ФГБОУ ДПО РМАНПО

акад. РАН, д-р мед. наук, проф., зав. каф. онкологии и паллиативной медицины 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

Список литературы

  1. Press O.W. Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 2013; 31: 1496-8.
  2. National Comprehensive Cancer Network. NCCN guidelines lymphoma, version 1.2013. Available at http: //www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
  3. Friedberg J.W, Taylor M.D, Cerhan J.R et al. Follicular lymphoma in the United States: First report of the national Lympho Care study. J Clin Oncol 2009; 27: 1202-8.
  4. Morschhauser F, Seymour J.F, Feugier P et al. Impactof induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011; 22 (Suppl. 4): 89.
  5. Rummel M.J, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treament for patients with indolent and mantle-cell lymphomas: Anopen-label, multicentre, randomised, phase 3non-inferiority trial. Lancet 2013; 381: 1203-10.
  6. Flinn I.W, van der Jagt R.H, Kahl B.S et al. Anopen-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) infirst-line treatment of patients with advanced indolentnon-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study. Paper presented at: ASH 2012; Atlanta, GA.
  7. Witzig T.E, Vukov A.M, Habermann T.M et al., Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23 (6): 1103-8.
  8. Friedberg J.W, Vose J.M, Kelly J.L et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807-12.
  9. Merryman R, Edwin N, Redd R et al. Rituximab/Bendamustin and Rituximab/Cytarabine (RB/RC) induction chemotherapy for transplant-eligible patients with mantle-cell lymphoma: A pooled analysis of two phase 2 clinical trials and off-trial experience. American Society of Hematology Annual Conference 2018.
  10. Поддубная И.В., Бабичева Л.Г. и др. Результаты проспективной многоцентровой наблюдательной программы BENEFIT: оценка рутинного применения комбинированной терапии бендамустином и ритуксимабом с последующей поддерживающей терапией ритуксимабом у пациентов с рецидивами или рефрактерными индолентными В-клеточными лимфомами (иНХЛ). Практическая онкология. 2017; 18 (14): 376-88. [ Poddubnaia I.V., Babicheva L.G. i dr. Rezul'taty prospektivnoi mnogotsentrovoi nabliudatel'noi programmy BENEFIT: otsenka rutinnogo primeneniia kombinirovannoi terapii bendamustinom i rituksimabom s posleduiushchei podderzhivaiushchei terapiei rituksimabom u patsientov s retsidivami ili refrakternymi indolentnymi V-kletochnymi limfomami (iNKhL). Prakticheskaia onkologiia. 2017; 18 (14): 376-88.]
  11. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97 (1): 101-6.
  12. Kahl B.S, Bartlett N.L, Leonard J.P et al. Bendamustineis effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study. Cancer 2010; 116: 106-14.
  13. Martinelli G, Schmitz S.F, Utiger U et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28 (29): 4480-4.
  14. Taverna C, Martinelli G, Hitz F et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2016; 34 (5): 495-500.
  15. Knauf W.U, Lissichkov T, Aldaoud A et al. PhaseIII randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-84.
  16. Marcus R.E, Davies A.J, Ando K et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomised Phase III GALLIUM study. Abstract 6. 58th Annual American Society of Hematology Meeting, 3-6 December, 2016.
  17. Kahl B.S, Bartlett N.L, Leonard J.P et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116 (1): 106-14.
  18. Dewilde S, Woods B et al. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. J Med Economics 2014; 17 (2): 111-24, 1941-837X.
  19. Visco C, Finotto S, Zambello R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma in eligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-9.
  20. Sehn L.H, Chua N, Mayer J et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081-93.
  21. Fowler N, Kahl B.S, Lee P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 2011; 29: 3389-95.
  22. Fowler N, DeVos S, Schreeder M. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Kd) inhibitor GS1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent Non-Hodgkin lymphoma: Results from a phase I study. Paper presented at: ASH 2012; December 10, 2012; Atlanta, GA.
  23. Blum K.A, Christian B, Flynn J.M et al. A phase Itrial of the Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).Paper presented at: ASH 2012; December 8, 2012; Atlanta, GA.
  24. Rummel M.J, Al-Batran S.E, Kim S.Z et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 3383-9.
  25. Cheson B.D, Wendtner C.M, Pieper A et al. Optimaluse of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from aninternational consensus panel. Review Clin Lymphoma Myeloma Leuk 2010; 10: 21-7.
  26. Caimi P.F, Barr P.M, Berger N.A et al. Non-Hodgkin’s lymphoma in the elderly. Drugs Aging 2010; 27: 211-38.
  27. Preiss R, Teichert J, Poеnisch W et al. Pharmacokinetic sand toxicity profile of bendamustine in myeloma patients with end-stage renal disease. Hematol J 2003; 4 (Suppl. 1): abstract 394.
  28. Alamdari H.S, Pinter-Brown L, Cassarino D.S et al. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 2010; 16: 1.
  29. Cephalon. Treanda: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/ 022303lbl
  30. Glance L.E, Cumpston A, Kanate A et al. Bendamustine-associated hemolytic anemia. Ann Pharmacother2009; 11: 1903-6.
  31. Tombleson R.L, Ho V, Sokol L et al. Optimizing premedications in the prevention of bendamustine in fusion-related reactions. Cancer Control 2012; 3: 245-7.
  32. Carter S.J, Bernstein S.H, Friedberg J.W et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011; 35: e223-224.
  33. Tsutsumi Y, Ogasawara R, Miyashita N et al. HBV reactivation in malignant lymphoma patient streated with rituximab and bendamustine. Int J Hematol 2012; 95: 588-91.
  34. Lim S.H, Pathapati S, Langevin J et al. SevereCMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2011; 91: 643-4.
  35. Schöffski P, Seeland G, Engel H et al. Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11: 729-34.
  36. Friedberg J.W, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: Results from a phase II multicenter, single agent study. J Clin Oncol 2008; 10: 26: 204-10.
  37. Cheson B.D, Friedberg J.W, Kahl B.S et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 452-7.
  38. Burke J.M, van der Jagt R.H.C et al. Differences in Quality of Life between Bendamustine-Rituximab and R-CHOP/R-CVP in patients with previously untreated advanced indolent non-Hodgkin Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leukaemia 2016; 16 (4): 182-90.
  39. Owen J.S, Melhem M, Passarell J.A et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 2010; 66: 1039-49.
  40. Weide R, Feiten S, Friesenhahn V et al. Retreatmentwith bendamustine-containing regimens inpatients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphoma sachieves high response rates and some long lasting remissions. Leuk Lymphoma 2012 [Epub ahead ofprint].
  41. Burchardt C.A, Brugger W, Maschmeyer G et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R Vs. CHOP-R (NHL 1-2003 trial) of theStiL (Study group indolent Lymphomas, Germany). Blood 2009; 114: abstract 2679. Presented at ASH annual meeting, 2009.
  42. Rummel M.J, Lerchenmuеller C, Greil R et al. Bendamustine-rituximab induction followed byobservation or rituximab maintenance for newly diagnosed patients with Waldenstroеm’s macroglobulinemia: Results from a prospective, randomized, multicenter study (StiL NHL 7-2008 - MAINTAIN; ClinicalTrials.gov identifier: NCT00877214. Paper presented at: ASH 2012; December 9, 2012; Atlanta, GA.
  43. Visani G, Malerba L, Stefani P.M et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safeand effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419-25.
  44. Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30: 3209-16.
  45. Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocyticleukemia: Amulticenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-66.
  46. Federico M, Caballero B, Marcheselli L et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol 2018; 5 (8): e359-e367. doi: 10.1016/S2352-3026 (18)30090-5

© ООО "Консилиум Медикум", 2018

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах